Company profile

Ticker
ILMN
Exchange
CEO
Francis A. deSouza
Employees
Incorporated in
Location
Fiscal year end
Former names
Illumina Inc
SEC CIK
IRS number
330804655

ILMN stock data

(
)

Calendar

25 Oct 19
14 Dec 19
29 Dec 19

News

Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 907M 838M 846M 867M
Net income 234M 296M 233M 210M
Diluted EPS 1.58 1.99 1.57 1.41
Net profit margin 25.80% 35.32% 27.54% 24.22%
Operating income 308M 205M 204M 197M
Net change in cash -128M -327M 1.13B -202M
Cash on hand 1.82B 1.94B 2.27B 1.14B
Cost of revenue 259M 265M 262M 277M

Financial data from Illumina earnings reports

Financial report summary

?
Competition
Thermo Fisher ScientificBGICeresRoche HoldingSolexaLuminexBioceptAgilentThird WaveCareDx
Management Discussion
  • To enhance comparability, the following table sets forth unaudited condensed consolidated statement of operations data for the specified reporting periods, stated as a percentage of total revenue.
  • Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three and nine month periods ended September 29, 2019 and September 30, 2018 were both 13 and 26 weeks, respectively.
  • Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Total revenue relates primarily to Core Illumina for all periods presented.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: demand, extend, extended, single, slight, upfront
Removed: abroad, avoided, commitment, discounted, field, force, identification, specific, supply